PRALSETINIB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H32FN9O2
Molecular Weight	533.6015
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of PRALSETINIB

Structure Search

SMILES

Cc1cc(=Nc2cc(C)[nH]n2)[nH]c([C@@]3([H])CC[C@](CC3)(C(=N[C@@]([H])(C)c4ccc(nc4)-n5cc(cn5)F)O)OC)n1

InChI

InChIKey=GBLBJPZSROAGMF-BATDWUPUSA-N

InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19-,27-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C27H32FN9O2
Molecular Weight	533.6015
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Jun 26 12:57:54 UTC 2021` Edited by `admin` on `Sat Jun 26 12:57:54 UTC 2021`
Record UNII	1WPE73O1WV
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PRALSETINIB

Official Name

English

GAVRETO

Brand Name

English

PRALSETINIB [WHO-DD]

Common Name

English

(CIS)-N-((S)-1-(6-(4-FLUORO-1H-PYRAZOL-1-YL)PYRIDIN-3-YL)ETHYL)-1-METHOXY-4-(4-METHYL-6-(5-METHYL-1H-PYRAZOL-3-YLAMINO)PYRIMIDIN-2-YL)CYCLOHEXANECARBOXAMIDE

Systematic Name

English

CYCLOHEXANECARBOXAMIDE, N-((1S)-1-(6-(4-FLUORO-1H-PYRAZOL-1-YL)-3-PYRIDINYL)ETHYL)-1-METHOXY-4-(4-METHYL-6-((5-METHYL-1H-PYRAZOL-3-YL)AMINO)-2-PYRIMIDINYL)-, CIS-

Systematic Name

English

BLU-123244

Code

English

X581238

Code

English

BLU123244

Code

English

PRALSETINIB [INN]

Common Name

English

X-581238

Code

English

PRALSETINIB [USAN]

Common Name

English

BLU-667

Code

English

Classification Tree Code System Code

FDA ORPHAN DRUG

634318

Created by admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021

FDA ORPHAN DRUG

728519

Created by admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021

Code System Code Type Description

CAS

2097132-94-8

Created by admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021

PRIMARY

PUBCHEM

129073603

Created by admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021

PRIMARY

NCI_THESAURUS

C132295

Created by admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021

PRIMARY

RXCUI

2394936

Created by admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021

PRIMARY

EVMPD

SUB196574

Created by admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021

PRIMARY

INN

11004

Created by admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021

PRIMARY

LACTMED

Pralsetinib

Created by admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021

PRIMARY

FDA UNII

1WPE73O1WV

Created by admin on Sat Jun 26 12:57:55 UTC 2021 , Edited by admin on Sat Jun 26 12:57:55 UTC 2021

PRIMARY

Related Record Type Details


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> INDUCER


					VK4SQL11C0

CYTOCHROME P450 1A2

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MINOR


					66DDF797LP

OATP-8

TRANSPORTER -> INHIBITOR


					76UB6O122H

ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2

TRANSPORTER -> INHIBITOR


					L9DP834D1P

CYTOCHROME P450 2C9

METABOLIC ENZYME -> INHIBITOR


					805SU96HKF

CYTOCHROME P450 3A5

METABOLIC ENZYME -> INHIBITOR

Interaction Type:

TIME-DEPENDENT INHIBITION


					1WPE73O1WV

EXCRETED UNCHANGED

Qualification:

FECAL

Amount:


					AIN96D6SGL

OATP1B1

TRANSPORTER -> INHIBITOR


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> INHIBITOR

Interaction Type:

TIME-DEPENDENT INHIBITION


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> INHIBITOR


					WCI46BYD7T

BSEP

TRANSPORTER -> INHIBITOR


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MAJOR


					L9DP834D1P

CYTOCHROME P450 2C9

METABOLIC ENZYME -> INDUCER


					B46KUN2O9L

MATE-2

TRANSPORTER -> INHIBITOR


					8E4LAA4357

CYTOCHROME P450 2D6

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MINOR


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE


					76UB6O122H

ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2

TRANSPORTER -> SUBSTRATE


					1WPE73O1WV

EXCRETED UNCHANGED

Qualification:

URINE

Amount:


					I81U7H57XI

OAT-1

TRANSPORTER -> INHIBITOR


					L0423Z5LDW

CYTOCHROME P450 2C8

METABOLIC ENZYME -> INHIBITOR


					805SU96HKF

CYTOCHROME P450 3A5

METABOLIC ENZYME -> INDUCER


					L0423Z5LDW

CYTOCHROME P450 2C8

METABOLIC ENZYME -> INDUCER


					6NP3XSMIP3

MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1

TRANSPORTER -> INHIBITOR


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Comments:

Protein binding of pralsetinib is independent of concentration.

Interaction Type:

BINDING

Amount:

Related Record Type Details


					1WPE73O1WV

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
blood-to-plasma ratio	PHARMACOKINETIC

Volume of Distribution	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC				MULTIPLE DOSES

Tmax	PHARMACOKINETIC				SINGLE DOSE

Biological Half-life	PHARMACOKINETIC				SINGLE DOSE